Item 8.01 Other Events.

On June 29, 2020, Heron Therapeutics, Inc. (the "Company") issued a press release announcing that it had received a Complete Response Letter from the U.S. Food and Drug Administration on June 26, 2020 for the Company's New Drug Application for the investigational agent HTX-011, a long-acting, extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the management of postoperative pain (the "Press Release"). A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.



Exhibit No.   Description
99.1            Press Release, dated June 29, 2020
104           Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses